Novartis Vaccines & Diagnostics, Gmbh

University of Washington

Xoma Technology Ltd.

Asha Yabannavar

Keith Bruce Pfister

Allan S Wagman

Toni Beth Kline

Simon C Ng

Eric Harwood

Niels H Andersen

Jason Bowman

Alice L Erwin

Khisimuzi E Mdluli

Ribhi Shawar

Li Long

Mohammad Luqman

Sang Hoon Lee

Isabel Zaror

Deborah Hurst

Bao-lu Chen

Xiaofeng Lu

Niels H Anderson

Bao-Lu Chen

Mohammed Luqman

Daniel E Lopes De Menezes

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

Antagonist anti-CD40 monoclonal antibodies and methods for their use

Antagonist anti-CD40 antibodies

Antibacterial compounds of formula I are provided:  As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

Antibacterial agents

Growing community of inventors

Lafayette, CA, United States of America

Asha Yabannavar